Journal article
Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
Current topics in medicinal chemistry, v 23(5), pp 389-402
01 Jan 2023
PMID: 36593538
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Glioblastoma Multiforme (GBM) is a debilitating type of brain cancer with a high mortality rate. Despite current treatment options such as surgery, radiotherapy, and the use of temozolomide and bevacizumab, it is considered incurable. Various methods, such as drug repositioning, have been used to increase the number of available treatments. Drug repositioning is the use of FDA-approved drugs to treat other diseases. This is possible because the drugs used for this purpose have polypharmacological effects. This means that these medications can bind to multiple targets, resulting in multiple mechanisms of action. Antipsychotics are one type of drug used to treat GBM. Antipsychotics are a broad class of drugs that can be further subdivided into typical and atypical classes. Typical antipsychotics include chlorpromazine, trifluoperazine, and pimozide. This class of antipsychotics was developed early on and primarily works on dopamine D2 receptors, though it can also work on others. Olanzapine and Quetiapine are examples of atypical antipsychotics, a category that was created later. These medications have a high affinity for serotonin receptors such as 5-HT2, but they can also act on dopamine and H1 receptors. Antipsychotic medications, in the case of GBM, also have other effects that can affect multiple pathways due to their polypharmacological effects. These include NF-B suppression, cyclin deregulation, and -catenin phosphorylation, among others. This review will delve deeper into the polypharmacological, the multiple effects of antipsychotics in the treatment of GBM, and an outlook for the field's future progression.
Metrics
Details
- Title
- Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
- Creators
- Wireko Andrew Awuah - Sumy State UniversityJacob Kalmanovich - Drexel UniversityAashna Mehta - University of DebrecenHelen Huang - Royal College of Surgeons in IrelandToufik Abdul-Rahman - Sumy State UniversityJyi Cheng Ng - Universiti Putra MalaysiaRohan Yarlagadda - Rowan UniversityKarl Kamanousa - Drexel UniversityMrinmoy Kundu - Institute of Medical Sciences and Sum HospitalEsther Patience Nansubuga - University of LeedsMohammad Mehedi Hasan - Mawlana Bhashani Science and Technology UniversityMykola Lyndin - Sumy State UniversityArda Isik - Istanbul Medeniyet UniversityVladyslav Sikora - Sumy State UniversityAthanasios Alexiou
- Publication Details
- Current topics in medicinal chemistry, v 23(5), pp 389-402
- Publisher
- Bentham Science Publ Ltd
- Number of pages
- 14
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000980069200005
- Scopus ID
- 2-s2.0-85150819881
- Other Identifier
- 991021901414904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Chemistry, Medicinal